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1. Introduction 
Axillary nodal status is the most important prognostic factor for patients with breast cancer.  
Clinical assessment and imaging modalities are not always reliable.  
Surgical removal and histopathological examination of axillary lymph nodes remain essential 
methods of staging the axilla and planning breast cancer therapy (Chu et al, 2010; Perry, 2001) 
But whether axillary lymph node dissection improves survival remains controversial.  
Historically, nodal involvement was determined by conventional axillary dissection. (Gill, 
2009) 
Till 1990s conventional axillary dissection was performed in all women with breast cancer 
with great incidence of morbidities  such as pain, numbness, shoulder joint stiffness, 
scarring, infection and long term lymphoedema. (Mansel et al, 2006) 
Sentinel lymph node biopsy has recently been introduced in the treatment of women with 
breast cancer.  
The American Society of Clinical Oncology in 2005 (Lyman, 2005), and more recently the 
British Association of Surgical Oncology (Association of Breast Surgery, 2009) endorsed 
sentinel lymph node biopsy (SLNB) as the recommended method of staging early breast 
cancer in clinically node negative patients.  
The sentinel lymph node hypothesis is that the sentinel lymph nodes are the first nodes 
draining a tumor and that focused histological analysis of sentinel lymph nodes is predictive 
of the status of the regional nodes thus accurately staging the breast disease with lower 
incidence of complications. (Krag et al, 1998; Morton et al, 1992) 
Giuliano et al (Giuliano et al, 1994) demonstrated that the status of sentinel nodes, with 
respect to the presence of metastases, accurately reflected the metastatic content of the local 
nodal basin. 
Early works support the feasibility and accuracy of sentinel lymph node biopsy. 
However, the optimal management of the axilla remains uncertain as axillary lymph node 
dissection, sentinel lymph node biopsy and lymphoscintigraphy have been described as 
reliable alternative procedures.  
By combining preoperative lymphatic mapping with intraoperative gamma probe detection 
nuclear medicine procedures are increasingly used to identify and detect the sentinel node 
in breast cancer, and in other malignancies. 
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Some surgeons have begun to offer sentinel lymph node biopsy as an alternative to axillary 
dissection for women with small infiltrating breast cancer; axillary dissection is performed 
only if tumor is found in the sentinel lymph node. 
Moreover in the recent years percutaneous imaging guided localization has been 
increasingly used to diagnose carcinoma previously detected at screening mammography.  
In this setting sentinel lymph node biopsy is considered the gold standard for axillary 
staging according to the low rate of node metastasis in nonpalpable infiltrating breast 
cancer. 
2. Sentinel lymph node biopsy 
In contrast to the procedure of lymphoscintigraphy for melanoma, in breast cancer there has 
not yet been reached a consensus for many topics regarding sentinel lymph node biopsy 
methodology such as tracer characteristics, injection volume, and principally the site of 
administration.  
2.1 Tracer characteristics 
Sentinel lymph node biopsy is commonly performed using radioisotopes and/or blue dye 
that facilitate sentinel lymph node mapping. (Jakub et al, 2010) 
However, it is still undefined which reagent is more suitable for lymphoscintigraphy. 
Several data from literature suggest that radioisotopes based on technetium-99m colloid are 
superior to blue dye in detecting SLN in breast cancer. (Somasundaram et al, 2007) 
Historically, the colorimetric detection of lymph nodes by the trypan blue (or equivalent) 
preceded the use of radioisotopes. For its rapid migration kinetics, the dye is injected in 1-4 
ml intra-operatively either into or around the tumour, or superficially into the section of 
areolar tissue that correlates with the index quadrant, 5 to 10 minutes before surgery. Patent 
blue dyes bind to interstitial albumin and are taken up by local lymphatic tissue. The 
efficiency with which the lymphatics are converted to bright blue channels by the vital dyes 
reflects their small hydrodynamic diameter, their ability to disperse quickly and even their 
capacity to readily progress through and beyond the nodes. The dissection is guided by the 
path of the blue lymphatic channels that lead to one or more nodes, more or less intensely 
colored. The choice of vital dye varies between operating surgeons. In the United States, 
Isosulfan blue, as a 1% sterile solution is the vital dye approved for use in humans by the 
Food and Drug Administration. Isosulfan blue is a monosodium isomer of the 2,5 
disulfonated triphenylmethanes which are also known as the patent blue dyes (Leong et al, 
2000). One of these patent blue dyes, Patent Blue Violet (or Patent Blue V), is preferentially 
used in Australia and Europe. Another vital dye, Indocyanine green has been used in Japan. 
All the vital dyes are selectively absorbed into lymphatic tissue and therefore facilitate 
localisation of the lymphatic channels and nodes. (White et al, 2011) 
After the introduction of the isotope method, some teams have remained faithful to the 
colorimetric method while others are converted to the exclusive use of the radiocolloides; 
but the majority of teams use the combination of the two techniques (Tafra et al, 2002), the 
results are usually best with only one, like a radiocolloide. The advantage of vital dyes is 
their “real time” efficiency in guiding the gamma probe to the sentinel node. This reduces 
exploratory dissection and tissue plane disruption and leads to a surgical exploration much 
less aggressive than with isotope technique, which has the advantage of transparency of the 
tissues to the gamma photons. Moreover the injection of blue presents a number of 
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disadvantages, the most serious is the risk of allergic shock, whose incidence is 
approximately 1%; review of the data suggests otherwise that the risk of severe anaphylaxis 
(grade 3) can be as low as 0.06%, and up to 0.4% for patients undergoing SLNB when data is 
analysed from large trials or databases. (Barthelmes et al, 2010; Hunting et al, 2010) 
Methylene blue has been used as an alternative to the other vital dyes. Its attraction as a 
mapping agent is its low risk profile. The risk of anaphylaxis from patent blue dyes may 
also be reduced by pre-operative prophylaxis with corticosteroids, antihistamines and H2-
receptor antagonists.  
In a study published recently Derossis and al. (Derossis et al, 2001) show that the rate of 
identification of the sentinel node by dye ganglion has remained stable over time (89% in the 
first 500 patients and 90% in the last 500 patients) while it has increased with the isotopic 
technique (respectively from 88% to 98%)(p < 0.0015). Moreover blue dyes also contribute to 
increased sensitivity of the SLNB procedure when used in conjunction with radioactive 
nanocolloids. 
Sentinel node biopsy (SNB) by radioisotopes is a widely accepted and reliable surgical 
method for staging breast cancer in patients with unknown positive axillary lymph nodes 
involvement.  
The reproducibility of lymphoscintigraphy for sentinel node detection varies from 85% to 
88% and the method appears to have a high interobserver agreement. 
Injection of the radio-isotope occurs between 2 and 24 h before surgery. Radioactive 
nanocolloid is injected preoperatively, with the assistance of radiological imaging either 
around the tumour, or into the overlying skin. It is thought that nanocolloids become 
entrapped within the sentinel lymph nodes either through a function of their particulate size 
(the larger hydrodynamic diameter of 50-100 nm for nanocolloid requires a transit time of 
usually more than 1 h and 15 min) or because of phagocytosis by leukocytes which migrate 
to and are retained within the draining lymph nodes. These entrapment processes are 
unlikely to be mutually exclusive, and other mechanisms may also exist, but the end result 
is localisation of the nanocolloid within the sentinel nodes rather than its diffuse spread to 
secondary nodes (Cody et al, 2001). 
2.2 Site of administration 
The exact site of injection of the mapping agent varies between studies, but can be broadly 
divided into “superficial” or “deep”. (Nieweg et al, 2004; Celliers et al, 2003) 
Lymphoscintigraphy by subdermal tracer administration is able to detect axillary lymph 
nodes in 98% of the cases but the method is accompanied by a low visualization incidence of 
drainage outside the lower axilla such as the internal mammary chain. This latter aspect 
appears to occur in 16% to 35% in the series using peri- or intratumoural administration 
with an axillary rate of visualization of 75% to 98%. Although peritumoural administration 
is predominantly associated with late lymph node detection, the early appearance observed 
after subdermal and intratumoural tracer injection justifies the obtention of early gamma 
camera images (McMasters et al, 2001; Boolbol et al, 2001). Intradermal injection delivers 
macromolecules to loco-regional lymph nodes faster than subcutaneous injection, 
suggesting easier lymphatic vessel access. Although the majority of patients has different 
pathways of lymphatic drainage from the ipsilateral breast and upper limb, in a small 
minority of patients the drainage pathway is through a common SLN. Such patients may be 
at increased risk of developing upper limb breast cancer-related lymphoedema after SLN 
biopsy (Cody et al, 1999). 
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The best injection site remains a hotly debated topic. The options are injected intratumor, 
peritumoral, subareolar, periareolar, subcutaneous and intradermal. The number of 
injection sites is variable, ranging between one and six. 
Most authors agree intratumoral site. Other methods of injection have all excellent results, 
without any real objective comparisons have been made, but now the simplest and most 
favorable for the intraoperative detection, is the intradermal periareolar apprauch. 
2.3 Injection volume 
The choice of an intradermal injection allows only a small volume (0.2 mL) per injection. 
When the intradermal injection is not possible there is a disagreement between American 
and European teams.  
The first team is for a large volume (up to 6 mL) to dilate the lymphatic channels and force the 
passage of the suspension of radiocolloid to the sentinel node. In contrast, the European teams, 
particularly under the impetus of the European Institute of Oncology in Milan, defend the 
injection of a small volume (0.1 to 0.4 mL) according to best physiological conditions.  
The debate is difficult because the reported results are excellent in both cases.  
Moreover, some prominent American teams also began to advocate a volume of 0.1 mL.  
2.4 Histopathological analysis 
The histopathological analytical methods for excised sentinel lymph nodes have been 
improved in order to increase staging accuracy and reduce false-negative rates.  
The dissected tissue containing the sentinel lymph node  is placed in 4% formalin solution. 
Frozen slide analysis is not performed. The sentinel lymph nodes are separated from 
surrounding adipose tissue, bisected, lamellated and embedded. Subsequent serial sections 
are made.  
The relevant sentinel lymph node pathology must include multisection staining with 
hematoxylin and eosin.  
Immunohistochemical analysis with antibodies to cytokeratin is also commonly used for 
hematoxylin and eosin-negative cases and may facilitate the detection of small deposits, 
thereby enhancing the screening of sentinel lymph nodes sections. 
The majority of sentinel lymph node cases can be classified as positive or negative based on 
the presence or absence of macrometastasis. The 2003 edition of the TNM classification uses 
2.0 mm as the cutoff size that distinguishes between micro- and macrometastasis. 
The cutoff value for isolated tumor cells or so-called submicrometastasis is 0.2 mm.  
The significance and practical relevance of micrometastases, isolated tumor cells and the 
value of immunohistochemical analysis also require further definition. 
2.5 Axillary excision complications 
Lymphedema is one of the most feared complication of breast cancer surgery.  
Sentinel lymph node biopsy has markedly reduced its incidence but has not eliminated it. 
The incidence of measured lymphedema after sentinel lymph node biopsy has been 
reported to be 0 to 22%; most studies report an incidence of 3 to 7%.  
The prevalence of subjectively reported lymphedema ranges from 0 to 15%. (Veronesi et al, 
2003; Leidenius et al, 2005; Langer et al, 2007; McLaughlin et al, 2008; Armer J et al, 2004; 
Lucci A et al, 2007; Crane-Okada et al, 2008; Helyer LK et al, 2009; Schrenk et al, 2000; Kwan 
et al, 2010 ) 
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The variation in incidence rates is influenced by the length of follow-up after the axillary 
surgery, by the absence of a standard definition of both measured and perceived lymphedema, 
and by the lack of agreement between patient perceptions and objective measures. 
Many authors have shown that in women treated for breast cancer, there is a large variation 
in the prevalence of lymphedema depending on the definition used. In their population of 
211 women treated for breast cancer, they found the incidence of lymphedema at 30 months 
post-treatment varied widely depending on the measure and definition used: 91% using the 
definition of a 2-cm difference in arm circumference, 67% using the definition of a 200-ml 
increase in volume by perometry, 45% using the definition of a 10% increase in volume by 
perometry, 41% using self-report of limb heaviness or swelling (Armer et al 2009). 
Dayes et al (Dayes et al, 2006, 2008) found that more than 20% of women presenting 
(presumably with the perception of arm swelling) to lymphedema clinics at large regional 
cancer centers had no measurable lymphedema (5% excess arm volume compared with the 
contralateral arm). Similarly, Querci della Rovere et al (Querci della Rovere et al, 2003) 
reported on a series of 199 patients, 10% (20 of 199) of whom perceived current arm 
swelling. Half of these patients with perceived swelling were not found to have objectively 
measured lymphedema by circumferential measurements. 
Women who had surgery on  their nondominant axilla less frequently reported perceived 
arm swelling in the absence of measured arm swelling, and less frequently perceived arm 
swelling even when there was objectively measured lymphedema. This suggests that patient 
perceptions of lymphedema are less influenced by sensory changes in the nondominant arm 
compared with the dominant arm. 
It  is possible that patient perceptions of lymphedema are influenced by patient knowledge 
of the number of nodes that was removed at the time of the sentinel lymph node biopsy. 
2.6 Limitations 
Several factors affect the technical success of sentinel lymph node. First of all the success rate 
is higher with experience. 
The reported technical success rates for sentinel lymph node biopsy are 69%-99% for 
radioisotope alone, 67%-93% for blue dye alone and 90%-100% for the combined use. 
Radioisotopes injection allows the surgeon to identify the sentinel nodes prior to making any 
incision, blue dye allows the surgeon to visually identify the sentinel nodes; the combined 
method may shorten the learning curve and increase the likelihood of technical success.    
The main limitation of this method is due to the appearance of false negatives that may be 
caused by tumor lymph node blockage of the sentinel lymph node and uptake in the 
neighboring lymph nodes. Infiltered sentinel nodes are generally increased in size and firm. 
Thus, they can be detected by intraoperative palpation, even when there is no uptake by the 
radiotracer. Intraoperative axillary palpation, once the sentinel lymph node is done, reduces 
the false negative rate.  
Moreover identification of sentinel lymph node is dependent on uptake of the labeling agent 
by the lymphatic pathway that drain the tumor. Previous surgery or surgical biopsy may 
disrupt this lymphatic pathway thus lowering the success rate and the accuracy of sentinel 
lymph node biopsy. Krag et al (Krag et al, 1998) reported a significantly higher frequency of 
failure to identify a hot spot in women who had undergone prior surgical biopsy  when 
compared to women that have undergone percutaneous breast biopsy or no surgical biopsy 
at all. Other authors did not find a significant difference between the groups.  
www.intechopen.com
 
Radioisotopes – Applications in Bio-Medical Science 
 
264 
A reduced identification rate in older patients is consistently reported. The increased fatty 
tissue in the breast in elderly patients might cause a decreased lymphatic flow. It is also 
suggested that the replacement of lymph nodes by fatty tissue decreases the capacity of 
lymph nodes to retain the radioactive colloid. 
Tumor size is also associated with the detection rate, showing a low identification rate in 
tumors >5 cm in size. Patients with large tumors have in fact a greater risk of extensive 
axillary tumor burden, which decreases the lymphoscintigraphic visualization. 
3. Radioguided occult lesion localization 
With increasing awareness of early breast cancer detection among the population, the use of 
mammography and breast ultrasound in screening has gained prominence in recent years.  
As a result, small non-palpable occult breast lesions are detected with increasing frequency. 
These lesions are initially characterised by percutaneous biopsy. If these turn out to be 
malignant, in terms of being invasive or in situ, or heterogeneous (such as atypical ductal 
hyperplasia, radial scar, papillary lesions, or those with imaging-pathologic discordance), 
diagnostic or therapeutic surgical excision becomes warranted.  
It is then necessary to accurately localize such occult breast lesions, with the aim to excise 
the smallest amount of breast tissue and yet remove the entire lesion whilst achieving 
adequate clear margins.  
A variety of preoperative localisation techniques for nonpalpable breast lesions has been 
described in the literature: hypodermic needles, wires (the most widely accepted technique), 
carbon solution, methylene blue dye. For the past 10 years, the radioguided occult lesion 
localisation (ROLL) technique has also been proposed either by means of radiotracer 
injection or by intratumoral deposits of radioactive seeds, and its role has been increasing in 
recent years.  
3.1 Hookwire localization 
For years, hookwire localization has been the traditional localization procedure in patients 
undergoing lumpectomy or wide local excision of clinically occult breast lesions (Chen et al, 
2005). 
This technique has several well described disadvantages such as incidental migration, 
kinking or fracture of the wire, and difficult logistics between the radiology, surgical and 
nuclear medicine departments.  
Moreover  hookwire localization has a number of other drawbacks.  
Negotiating the wire through a very dense breast can be technically difficult for radiologists. 
The hookwire may be imprecisely placed or even displaced in fatty breasts, which is of 
particular concern when a patient has to move from one centre to another for surgery. The 
pathologist may find the wire difficult to dissect, with possible subsequent damage to the 
specimen.  
3.2 ROLL radioguided occult lesion localization 
Radioguided occult lesion localization  is a new technique which allows identification of non 
palpable breast lesion in breast cancer using, on the model of sentinel node procedure, 
injection of a radiotracer over the tumour lesion. With a gamma detection probe, it is then 
possible during surgery to identify the lesion. (Belloni et al, 2011) 
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Radioguided occult lesion localization was pioneered in 1996 at the European Institute of 
Oncology, Milan. Inspired by the rationale for sentinel node biopsy, radioguided occult 
lesion localization involved the inoculation of macroaggregates of human serum albumin 
labelled with radioactive technetium99 (99mTc) directly into the site of a nonpalpable breast 
lesion, with mammography or ultrasound guidance. After radiotracer injection, a gamma-
detecting probe was used to locate the lesion during surgery, allowing the surgeon to 
evaluate its skin projection and decide the best approach with an acceptable cosmetic 
outcome (Luini et al, 1998). 
After the first publications on ROLL it was proposed that human serum albumin should be 
used as a radiotracer, with large particles ranging from 10 to 150 μm in diameter. For 
radioguided localisation of non-palpable breast lesions it is preferable that radiotracers do 
not migrate rapidly by lymphatic channels, in order to allow lesion identification by the 
surgeon using the probe. For this reason, it is recommended that larger 99mTc-labelled 
colloid particles of albumin should be used than are employed for sentinel lymph node 
identification, for which small particles from 200 to 1,000 nm are preferred. Other small 
particles, such as sulphur colloid, which are used in most services in the United States, flow 
quickly to the axillary lymph nodes and are often trapped in several nodes. 
99mTc-labelled dextran was first used in lymphoscintigraphy by Henze et al in 1982 (Henze 
et al, 1982) that demonstrated its usefulness in SLN mapping in breast carcinoma, achieving 
successful identification of the SLN in 98% of cases. The sensitivity of SLN biopsy in 
predicting axillary node status was 100%, with no false-negative results. Another argument 
in favour of dextran is its low cost: it is much less expensive than human albumin. 
Radiation safety to patient and staff in radioguided occult lesion localisation procedures has 
been secured and radioguided occult lesion localization is considered a reliable and safe 
alternative to wire localization.  
Technetium-99m has a short half-life of 6 hours and low-dose gamma radiation is used. 
Cremonesi et al (Cremonesi et al, 1999) calculated the effective dose for  patient, which is 
9.25 μSv, less than half the dose of a chest X-ray (0.02 mSv). 
Radiation due to additional mammograms needed for hookwire localization (1-2 mSv) may 
exceed that involved for 100 to 200 radioguided occult lesion localisation procedures. 
Finger doses to breast surgeons and radiologists are also minimal, as stated by Rampaul et 
al (Rampaul et al, 2003) and amount to 9.3±3.3 mSv and 0.5±0.1 mSv, respectively. 
The advantages of this technique can be summarised as: precise localisation and accurate 
surgical removal; reduction of tissue damage in the final pathological specimen (as the wire 
is not present in the specimen); accurate frozen section (if indicated); improved rate of clear 
margins; reduced size of the excised specimen; increased patient comfort; decreased 
operative time; and reduced number of reoperations (cost effectiveness). 
One of the important drawbacks of such a technique is radiotracer spillage within the 
mammary gland that makes the precise lesion resection difficult, and this requires the use of 
a hook-wire collocation to reach the lesion. The possibility of obtaining an intraoperative 
image of the specimen could help to confirm whether the lesion is correctly removed. Some 
types of portable gamma cameras have been designed, but up to now, intraoperative use 
has been confined to surgery of parathyroid adenomas and sentinel lymph node location. 
The intraoperative acquisition of such images can predict the involvement of surgical 
margins, avoiding future surgical procedures. 
Reported advantages of radioguided occult lesion localization are (van der Ploeg et al, 2008): 
precise localisation and accurate surgical removal, reduction in the tissue damage within the 
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final pathological specimen, accurate frozen section (in the case a differential diagnosis is 
required between DCIS and invasive cancer), improved rate of clear margins avoiding the 
emotional trauma of another operation, reduced size of the excised specimen, better 
concentricity of the lesion, increased patient comfort, decreased operative time, and reduced 
rate in re-do surgery reducing costs. Moreover no control mammogram is needed after 
localisation, allowing reduction in both costs and radiation dose. 
When comparing the radioguided occult lesion localization technique with the hookwire 
localization in the radioguided occult lesion localization group between 69% and 84% of the 
lesions were radically excised, compared with 44-60% of the lesions in the hookwire 
localization group.  
The studies that combined radioguided occult lesion localization and the sentinel node 
procedure mentioned even higher percentages of radically excised specimens ranging from 
90% to 95% and an identification rate of sentinel nodes up to 100%, resulting in 
minimisation of the surgical intervention and a decrease in postoperative morbidity.  
One randomised controlled trial mentioned that the radioguided occult lesion localization 
procedure had a faster localisation time, was easier to perform, was less painful and gave a 
better cosmetic result than hookwire localization. 
Many studies have reported good margin clearance with radioguided occult lesion 
localization, which ranged from 75 to 100%. In a recent publication, the free margin 
clearance rate was 84% after radioguided occult lesion localization compared with 60% after 
hookwire localization. 
An important advantage of the ROLL technique is that it takes advantage of the radioactive 
tracer that is used anyway to detect the sentinel node. Therefore, it is not necessary to use a 
separate injection for the SN detection as was used in some studies. Feggi et al (Feggi et al, 
2001) demonstrated successfully, that it is possible to perform ROLL and sentinel lymph 
node mapping with a single injection of Technetium-labelled Nanocolloid.  
Ductal migration of isotope is an uncommon problem with radioguided occult lesion 
localization. 
Another constraint is the timing of surgery, which has to be performed within 4 hours of 
radioactive occult breast lesion localization completion, lest the tracer count is not high 
enough to enable accurate gamma probe–guided excision. 
3.3 SNOLL sentinel node and occult lesion localisation 
Sentinel node localization can be performed together with radioguided occult lesion 
localization. (Strnad et al, 2006)  
How to execute lymphoscintigraphy in patients with non-palpable lesions scheduled to 
undergo radioguided surgery for the primary lesion is still the subject of debate; it is not 
clear whether it is better to employ a single tracer and single injection method, as recently 
proposed, or a dual tracer method with injection at different sites. (Patel et al, 2004) 
Filtered Tc-99m labelled sulphur colloid with a particle size of smaller than 100 nanometers 
is injected. Tracers flow via the lymphatics and accumulate in the sentinel nodes. 
Subsequent scintigraphy can be performed as usual. The application of a radioisotope in 
sentinel node and occult lesion localization has revolutionized the original two-step 
procedure into one with very promising results.  
Otherwise some authors report that  a dual administration of radiopharmaceuticals, i.e. the 
radioguided occult lesion localization procedure with intralesional injection of 
macroaggregates of 99mTc-labelled human serum albumin  followed by lymphoscintigraphy 
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with subdermal injection of nanocolloids, represents the best approach to localise both non-
palpable lesions of the breast and axillary sentinel nodes on the same day.  
Also the Italian group of the European Institute of Oncology (De Cicco et al, 2004, 2002) 
confirmed in a recent paper that the combination of the ROLL procedure with direct 
injection of human serum albumin into the lesion and lymphoscintigraphy performed with 
subdermal injection of radiocolloids represents the method of choice for accurate 
localisation of both non-palpable lesions and sentinel nodes. 
3.4 RSD radioactive seed localization 
There are a few reports describing alternative techniques to localise non-palpable breast 
lesions. In 2001, Gray et al (Gray et al, 2001) reported on a refinement of the technique of 
radioguided surgery. In this technique, known as “radioactive seed localization” (RSL), a 
radio-opaque titanium seed containing Iodine-125 is inserted into the tumor under stereotactic 
or ultrasound guidance, and the gamma probe is again used to guide surgical resection.  
Use of radioactive seed localization such as an iodine-125-radiolabelled (I-125) seed for 
localization of non-palpable breast tumours could potentially prevent the problems related 
to hookwire localization and seems a promising approach for the resection of nonpalpable 
breast lesions. (Barros et al, 2002) 
Radioactive seed localization  is at least equivalent compared with wire localization in terms 
of the ease of the procedure, removing the target lesion, the volume of breast tissue excised, 
obtaining negative margins, avoiding a second operative intervention, and allowing for 
simultaneous axillary staging.  
Radioactive seed localization is safe, effective, and compared to wire localization, reduces 
the rates of intraoperative re-excision and reoperation for positive margins by 68%. Patient 
satisfaction is improved with radioactive seed localization.  
RSL has been reviewed by Jakub et al (Jakub et al, 2010). Subsequent randomized and non-
randomized trials have shown improvements in positive margin rates compared to standard 
hookwire guided localization. In studies of both radioguided occult lesion localization and 
radioguided seed localization, there was rapid adoption by surgeons and radiologists, and 
satisfaction and acceptance by patients. 
3.5 Probes 
Currently, tumoral harvesting is aided by using a hand-held gamma probe. This device 
locates the highest activity point and the point where activity fades, thus indicating the 
surgical resection margins. Once the tumour has been removed, handheld scanning of the 
surgical area will confirm that activity is only located within the tumoral specimen and that 
there is no residual activity requiring further excision. 
Intraoperative probes are capable of detecting a very low flow of gamma photons. The 
sensitive part is at the end of a cylindrical tube of 1 to 2 cm in diameter. To ensure sterility, 
the tube is slipped into a long sleeve sterile flexible plastic disposable. It is connected by 
cable to an electronic unit which analyzes the signal, displays the count rate and beeps 
modulated by the level of radioactivity detected. The detection of gamma photons is 
ensured either by absorption in a scintillating crystal type sodium iodide or cesium iodide 
activated with thallium (NaI (Tl) or CsI (Tl)) or in a semiconductor-type cadmium-tellurium 
( Cd-Te) and cadmium-zinc-telluride (Cd-Zn-Te, sometimes abbreviated as CZT). In the first 
case, the signal emitted by the crystal must be amplified by a photomultiplier vacuum tube 
powered by a voltage of about 1000 volts, whereas with the semiconductor signal is 
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processed immediately in low voltage and the system does not include a photomultiplier. 
However, detection volume identical stopping power and hence the detection sensitivity of 
sparkling crystals are higher than those of semiconductors. 
The intraoperative detection probes currently available have a very high sensitivity to 
gamma photons emitted by technetium-99m. They are also capable, with a setting often 
already pre-programmed to detect the emission of other isotopes commonly used in nuclear 
medicine (indium 111, iodine 131), even as the signal from the positron emitters such as 18-
fluoro- deoxyglucose (FDG). (Paredes et al, 2008) 
Many studies showed that the use of a portable c-camera equipped for simultaneous 99mTc 
signal and Gd-153 pointer signal display can improve sentinel lymph node excision 
identification in breast carcinoma, prostate cancer, melanoma and other cutaneous 
malignancies.  
Furthermore some authors adfirm that intraoperative realtime imaging by a c-camera can be 
used as an additional technique, besides preoperative lymphoscintigraphy, preoperative 
SPECT ⁄ CT and the intraoperative application of a hand-held c-probe (Cho et al 2009). 
4. Radioguided localization after neo-adjuvant chemotherapy 
The use of neo-adjuvant chemotherapy has increased in the treatment of loco-regionally 
advanced primarily operable breast cancer. As a result of improved neo-adjuvant 
chemotherapy regimens the number of clinical as well as radiological responses have 
increased. In case of a complete response it is difficult to identify residual disease and to 
perform an adequate radical breast-conserving surgery. Therefore localization of the 
original tumour bed is mandatory. The (125)I has a half-time of 60 days and is therefore still 
recognisable with a gamma probe after admittance of several courses of neo-adjuvant 
chemotherapy. (125)I seed localization is a highly successful technique in localizing the 
tumour bed in patients who receive neo-adjuvant chemotherapy for breast cancer leading to 
a high percentage of radical margins in case of breast-conserving surgery. (Straver et al, 
2010a, 2010b; van Riet et al, 2010) 
Nontheless an important benefit of neoadjuvant chemotherapy is the increased potential 
for breast-conserving surgery. At present also the response of axillary lymph node 
metastases to chemotherapy is not easily assessed, rendering axilla-conserving treatment 
difficult.  
The tumour response in the marked lymph node may be used to tailor further axillary 
treatment, making axilla-conserving surgery a possibility. Moreover the high accuracy in 
visualizing lymph node metastases and the sufficiently high SUV(max) and tumour to 
background ratio at baseline suggest that it is feasible to monitor the axillary response with 
FDG PET/CT, especially in triple-negative tumours. (Choi et al, 2010) 
5. Conclusion 
Screening mammography is allowing detection of early breast cancer in an increasing 
number of women with occult, locally invasive or in situ carcinoma. The result is a marked 
decrease in the mean size of lesions, an increase in the incidence of in situ carcinomas and a 
reduction in axillary node involvement. Nuclear medicine techniques can help surgeons to 
identify both the tumor and the sentinel lymph nodes in order to stage the disease. 
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